Details of the Drug Combinations

General Information of This Drug (ID: DM1T6ZN)

Drug Name
Pacritinib   DM1T6ZN
Synonyms JAK inhibitor (alone or in combination)s
Indication
Disease Entry ICD 11 Status REF
Myelofibrosis 2A20.2 Approved [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
Pacritinib + Mitomycin DCRA3UE Mitomycin Diffuse large B cell lymphoma (Cell Line: TMD8) [2]
------------------------------------------------------------------------------------
8 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Pacritinib + Decitabine DC4M4FH Decitabine Chronic Myelomonocytic Leukemia [3]
Pacritinib + Ibrutinib DC8F5TL Ibrutinib Chronic Lymphocytic Leukemia [4]
Pacritinib + Erlotinib DCJYKEM Erlotinib Non-Small Cell Lung Cancer [5]
Pacritinib + Azacitidine DCXJ1WS Azacitidine Chronic Myelomonocytic Leukemia [6]
Talazoparib + Pacritinib DCJ3JYK Talazoparib Primary Myelofibrosis [7]
Pacritinib + Fludarabine DCCBV19 Fludarabine Myeloproliferative Diseases [8]
Pacritinib + Decitabine DCDFMNE Decitabine Leukemia [9]
Pacritinib + Decitabine DC1ZE9Q Decitabine Acute Myeloid Leukemia (AML) [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DrugCom(s)

References

1 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 208712.
2 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3 ClinicalTrials.gov (NCT02564536) Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)
4 ClinicalTrials.gov (NCT02677948) Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
5 ClinicalTrials.gov (NCT02342353) Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)
6 ClinicalTrials.gov (NCT06159491) Pacritinib in CMML
7 ClinicalTrials.gov (NCT06218628) Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
8 ClinicalTrials.gov (NCT02410551) Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)
9 ClinicalTrials.gov (NCT02469415) Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
10 ClinicalTrials.gov (NCT02532010) Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML